A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors.

Trial Profile

A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Bleomycin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Ifosfamide (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
  • Indications Germ cell and embryonal neoplasms
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 May 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
    • 14 Jul 2009 Planned number of patients changed from 240 to 260 as reported by ClinicalTrials.gov.
    • 29 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top